Outlook Therapeutics risks Nasdaq delisting after 30-day sub-$1 bid-price stretch
OTLK•OTLK•OTLK•OTLK•Outlook Therapeutics received a Nasdaq notice after its shares closed below the $1.00 minimum bid price for 30 straight business days. The company has until March 24, 2027, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
Outlook Therapeutics said it received a Nasdaq notice for failing the $1.00 minimum bid-price rule after 30 consecutive business days below that level. Its shares remain listed on the Nasdaq Capital Market while the company has until March 24, 2027, to regain compliance by meeting the required price for 10 consecutive business days.
Failure to regain compliance could lead to a delisting determination, which the company may appeal to a Nasdaq hearings panel. An additional 180-day cure period may be available if the company meets eligibility requirements, including through a reverse stock split.
